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Introduction: Sacubitril/valsartan (SV) promotes cardiac remodeling and improves
prognosis in patients with heart failure (HF). However, the response to the drug may
vary between patients and its implementation in daily clinical practice has been slower
than expected. Our objective was to develop a score predicting the super-response to
SV in HF outpatients.
Methods: This is a retrospective analysis of 185 consecutive patients prescribed
SV from two tertiary hospitals between September 2016 and February 2018. Super-
responder was defined as a patient taking the drug and (i) without HF admissions,
death, or heart transplant, and (ii) with a ≥50% reduction in NT-proBNP levels and/or an
increase of ≥10 points in LVEF in a 12-month follow-up period after starting SV. Clinical,
echocardiographic, ECG, and biochemical variables were used in a logistic regression
analysis to construct a score for super-response to SV which was internally validated
using bootstrap method.
Results: Out of 185 patients, 65 (35%) fulfilled the super-responder criteria. Predictors
for super-response to SV were absence of both previous aldosterone antagonist and
diuretic treatment, NYHA I-II class, female gender, previous 1-year HF admission, and
sinus rhythm. An integrating score distinguished a low- (<25%), intermediate- (∼46%),
and high-probability (>80%) for 1-year super-response to SV. The AUC for the model
was 0.72 (95%CI: 0.64–0.80), remaining consistent after internal validation.
Conclusion: One-third of our patients presented a super-response to SV. We propose
an easy-to-calculate score to predict super-response to SV after 1-year initiation based
on variables that are currently assessed in clinical practice.
Keywords: sacubitril/valsartan, heart failure, super-response, score, cardiac remodeling
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INTRODUCTION
Sacubitril/valsartan (SV) is the first agent of the angiotensin
receptor–neprilysin inhibitor (ARNI) drug class (Singh et al.,
2017). In the PARADIGM−HF trial, ARNI compared to
enalapril reduced the risk of cardiovascular death or heart
failure (HF) hospitalization by 20%. Moreover, the risks of
all−cause, cardiovascular, and sudden cardiac death were also
significantly reduced by SV (McMurray et al., 2014). Therefore,
both American and European guidelines on HF recommend
SV for symptomatic HF patients with reduced ejection fraction
(HFrEF) (Ponikowski et al., 2016; Yancy et al., 2017).
Although the benefit of SV was consistent across the clinical
spectrum of HF (McMurray et al., 2014), the response to the drug
may vary between patients from real life and those from clinical
trial. In fact, the study population of the trial represented a subset
of a larger cohort eligible for the initial run-in period ensuring
tolerability of target doses of both enalapril and ARNI before
randomization (Desai et al., 2016). Previous studies (Pellicori
et al., 2017; Martens et al., 2018), and more recently, the
Prospective Study of Biomarkers, Symptom Improvement, and
Ventricular Remodeling During SV Therapy for Heart Failure
(PROVE-HF) study (Januzzi et al., 2019) have showed that
SV promotes reverse myocardial remodeling. Moreover, a sub-
analysis of this study showed that patients with a higher decrease
in NT-proBNP levels or in left ventricular end diastolic diameter
during the first 6 months after SV initiation had a lower rate of
HF hospitalizations or death in the following months (Januzzi
et al., 2020). However, the identification of such predictors of
super-response to ARNI is insufficient so far (Martens et al., 2018;
Nakou et al., 2018; Moliner-Abós et al., 2019; Vicent et al., 2019;
Chang et al., 2020; Díez-Villanueva et al., 2020). In addition,
since its approval in late 2015 the implementation of SV in daily
clinical practice has been poor, partially due to high cost (Di Tano
and Bettari, 2017; DeVore et al., 2018; Sangaralingham et al.,
2018; Kahn et al., 2020). So, the development of tools aimed to
recognize patients with a very favorable response to specific drugs
could improve the efficiency in a setting where pharmacological
treatment is increasingly complex and expensive.
Hence, we conducted a study aimed to determine the
prevalence and clinical predictors of super-response to SV.
MATERIALS AND METHODS
Study Population
This study includes a cohort of all consecutive patients
attended at the HF clinics from two tertiary referral centers
in Barcelona (Spain) since September 2016 to February 2018
in which SV was introduced. The clinical criteria for initiating
drug were (i) symptomatic HF defined as New York Heart
Association (NYHA) class II–IV, (ii) left ventricular ejection
fraction (LVEF) ≤ 40% measured by echocardiography, and
(iii) pretreatment according to the current European Society of
Cardiology (ESC) guidelines (Ponikowski et al., 2016) (including
ACEI or ARB). All procedures performed in the study were
in accordance with the ethical standards of the institutional
research committee and with the Helsinki declaration. Due to the
retrospective nature of the study, it was considered that informed
consent was not required.
Study Variables
Data were collected using the electronic health record of both
hospitals. The following clinical variables were gathered at study
inclusion and during the follow-up period: demographic and
previous clinical history, NYHA functional class, systolic blood
pressure, laboratory blood tests including NT-proBNP within the
previous 30 days before SV initiation, ECG, echocardiography
within the previous 6 months, and pharmacological and non-
pharmacological treatment.
Super-Response to SV and Follow-Up
After initiation of SV, the frequency of the follow-up visits was
performed at the discretion of the attending cardiologist. Most of
the patients were visited every 2–4 weeks at the HF clinic of each
center, with renal function, potassium, and clinical status check.
Once the drug was up-titrated until maximum tolerated dose, a
new determination of NT-proBNP and echocardiography were
usually done. The incident HF follow-up duration was calculated
as the time from starting SV until the time of censoring: death,
heart transplantation, or a 12-month complete period. Over
a similar follow-up duration, the number of HF admissions
before the initiation of SV was calculated. Super-responder to
SV was defined as a patient taking the drug and (i) without
HF admissions, death, or heart transplant and (ii) with a ≥50%
reduction in NT-proBNP levels (Zile et al., 2016) and/or an
increase of ≥10 points in LVEF (Januzzi et al., 2019) in a
12-month follow-up period after starting the SV. The primary
objective was to determine the prevalence and predictors of
super-response to SV.
Statistical Analysis
Continuous variables were expressed as the mean ± standard
deviation (SD) or as median (interquartile range) and were
compared with the Student’s t-test, log-rank test. Categorical
variables were expressed as percentages and compared with the
χ2 or Fisher’s exact tests.
Variable selection was performed using logistic regression
models, with super-response to SV as a dichotomous dependent
variable. In order to find the best predictive model with the
highest area under the receiving operating characteristic (ROC)
curve (AUC), exploratory analyses were performed including
clinical meaningful variables showing a significant level in the
univariate analysis (p-value < 0.2) and prioritizing parsimony.
The internal validity of the final predictive model was tested
for 15 bootstrap re-samples, using the “CVAUROC” package
for Stata (Luque-Fernandez et al., 2019). The calibration of the
model was assessed by the Hosmer–Lemeshow test for goodness
of fit and plotting the observed frequencies against the expected
probabilities. Finally, a score of super-response was proposed as
the addition of the β coefficients of each predictor multiplied
by 10 and rounded to the nearest integer number. Mean
crossvalidated sensitivity and specificity for each category of the
score were presented. A two-sided p-value< 0.05 was considered
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Age, years 65 (13) 67 (12) 0.354 67 (12)
Sex, female 20 (31) 26 (22) 0.171 46 (25)
Ischemic etiology 30 (46) 59 (49) 0.695 89 (48)
NYHA class 0.090
I 2 (3) 2 (2) 4 (2)
II 47 (72) 67 (56) 114 (61)
III 16 (25) 49 (40) 65 (35)
IV 0 (0) 2 (2) 2 (1)
LVEF, % 31 (6) 31 (7) 0.708 31 (6)
LVEDD, mm 60 (9) 63 (9) 0.077 62 (9)
ECG rhythm 0.027
Sinusal 47 (72) 66 (55) 113 (61)
Atrial fibrillation 18 (28) 46 (39) 64 (35)
Pacemaker 0 (0) 7 (6) 7 (4)
SBP, mmHg 124 (15) 121 (20) 0.242 122 (18)
NT-proBNP, ng/L 1694 (888–4103) 1817 (898–3917) 0.982 1844 (891–4104)
Creatinine, mg/dL 1.1 (0.4) 1.1 (0.3) 0.651 1.1 (0.3)
GFR, mL/min/1.73 m2 70 (20) 68 (17) 0.637 69 (18)
GFR < 60 mL/min/1.73 m2 22 (35) 48 (40) 0.475 70 (38)
Potassium, mEq/L 4.4 (0.5) 4.5 (0.5) 0.340 4.5 (0.5)
ICD 16 (25) 45 (38) 0.075 61 (33)
CRT 8 (12) 20 (17) 0.417 28 (15)
Mitraclip 2 (3) 4 (3) 0.925 6 (3)
Levosimendan 10 (15) 15 (13) 0.584 25 (14)
ACEi/ARB 58 (89) 110 (92) 0.584 168 (91)
Beta-blockers 63 (97) 111 (93) 0.225 174 (94)
MRA 39 (60) 96 (80) 0.003 135 (73)
Ivabradine 10 (16) 21 (18) 0.728 31 (17)
Diuretics 44 (68) 99 (83) 0.022 143 (73)
Initial dose ARNI, mg 0.517
24/26 41 (63) 85 (71) 126 (68)
49/51 22 (34) 33 (28) 55 (30)
97/103 2 (3) 2 (2) 4 (2)
HF admission in last year 38 (59) 53 (44) 0.063 91 (49)
After 1 year follow-up
NYHA class <0.001
I 22 (34) 16 (16) 38(23)
II 39 (60) 54 (53) 93 (56)
III 4 (6) 29 (28) 33 (20)
IV 0 (0) 3 (3) 3 (1)
LVEF,% 42 (12) 33 (9) <0.001 36 (11)
≥10 points LVEF 36 (56) 10 (10) <0.001 46 (29)
NT-proBNP, ng/L 696 (259–1802) 1766 (850–3120) <0.001 1324 (574–2513)
≥50% of change in NT-proBNP 39 (66) 18 (16) <0.001 57 (33)
Creatinine, mg/dL 1.2 (0.4) 1.3 (0.7) 0.104 1.3 (0.6)
GFR, mL/min/1.73 m2 65 (21) 61 (20) 0.221 63 (20)
Final dose ARNI, mg <0.001
24/26 11 (17) 24 (20) 35(19)
49/51 14 (22) 18 (15) 32 (17)
97/103 40 (62) 41 (34) 81 (44)
Discontinuing 0 (0) 37 (31) 37 (20)
1-year HF admission 0 (0) 50 (42) <0.001 50 (27)
1-year heart transplant 0 (0) 8 (7) <0.001 8 (4)
1-year mortality 0 (0) 24 (20) <0.001 24 (13)
Results are expressed in number (%), mean (SD), or median (IQR). List of abbreviations: NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; LVEDD,
left ventricular end diastolic diameter; SBP, systolic blood pressure; NT-proBNP, NT amino terminal propeptide brain natriuretic peptide; GFR, glomerular filtration rate;
ICD, implantable cardioverter defibrillator; CRT, cardiac resynchronize therapy; ACEi, angiotensin cardioverter enzyme inhibitor; ARB, aldosterone receptor antagonist;
MRA, mineraloid receptor antagonist; ARNI, aldosterone receptor neprilysin inhibitor; HF, heart failure.
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FIGURE 1 | Probability of super-response to sacubitril/valsartan according to the AWARD-Class score categories.







Antialdosteronic naive 0.836 8 2.3 (1.1–4.8) 0.024
Woman 0.536 5 1.7 (0.8–3.6) 0.161
HF Admission in last year 0.601 6 1.8 (0.9–3.6) 0.088
Sinus Rhythm 0.692 7 2.0 (1.0–4.0) 0.052
Diuretics naive 0.743 7 2.1 (1.0–4.5) 0.059
I-II NYHA Class 0.835 8 2.3 (1.1–4.8) 0.025
List of abbreviations: OR, odds ratio; HF, heart failure; NYHA, New York
Heart Association.
statistically significant. All the analyses were performed using
STATA software (v. 13.1).
RESULTS
Prevalence of Super-Responders to
Sacubitril/Valsartan
Out of 185 patients, 65 (35.1%) fulfilled the super-responder
criteria. Of them, 29 patients presented an NT-proBNP reduction
of 50% or more, 26 improved LVEF at least 10 points, and,
finally, 10 patients accomplished both conditions. Overall, super-
responders were more frequent in sinus rhythm and without
aldosterone antagonists or diuretics at the time of SV initiation
than standard responders. Although non-significant statistically,
clinical characteristics such as women, NYHA I-II class, less
dilated left ventricle, and without implantable cardioverter
defibrillator were more frequent among super-responders. Lastly,
previous HF admission rate during the past year was higher
in the super-responder group. After a 1-year follow-up, super-
responders presented a better NYHA class, higher LVEF, lower
plasma levels of NT-proBNP, and similar renal function with
higher doses of SV compared to those with a standard
response. Table 1 summarizes the clinical characteristics of the
study population.
Predictors for Super-Response: The
AWARD-Class Score
After a multivariate logistic analysis, the absence of previous
aldosterone antagonist treatment (OR 2.3, 95% CI: 1.1–4.8)
and NYHA I-II class (OR 2.3, 95% CI: 1.1–4.8) were the
only independent predictors of super-response to SV. Along
with these two factors, the model which predicted best
the super-response to SV included gender, presence of HF
admission over the past year, ECG rhythm, and presence
of diuretics (AUC 0.720; 95% CI: 0.644–0.797). In order
to build a score able to predict the probability of super-
response for a given patient, we assigned a scale of 41 points
based on the β-coefficient of each variable (Table 2). This
score—the AWARD-Class score—allowed the estimation of the
chance of super-response to SV, as illustrated in Figure 1.
Indeed, this score distinguished a low- (24% event rate),
intermediate- (47% event rate), and high-probability groups (83%
event rate) for 1-year follow-up after SV initiation. Table 3
resumes the prognostic performance of the AWARD-Class score
in each category.
Internal Validation and Calibration of the
Model
After the bootstrap sampling, the AUC for this model was
0.738 (95% CI 0.616–0.792), which was non-statistically different
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TABLE 3 | Prognostic performance of the AWARD-Class score categories.
Sensitivity Specificity PPV NPV
Low score (0–20 points) 88% 32% 29% 89%
Intermediate score (21–30 points) 37% 90% 77% 62%
High score (≥31 points) 0% 100% 100% 17%
List of abbreviations: PPV, positive predictive value; NPV, negative predictive value.
FIGURE 2 | Comparison of the ROC curves of the derivation (curve containing
dots) and internal validation models. List of abbreviations: ROC, receiver
operating characteristic; AUC, area under the curve; P, p-value; NS,
non-significance.
compared to the AUC of the derivation cohort (Figure 2).
Calibration of the score was fairly good as shown by the
non-significant Hosmer–Lemeshow test (P = 0.820) and the
calibration plot (Figure 3).
DISCUSSION
Main Findings
Up to 35% of patients from two different tertiary hospitals
fulfilled the super-responder criteria to SV. This study proposes
a simple score that predicts super-response to SV after 1-year
initiation. Moreover, the score allows discrimination between
low-, intermediate-, and high-probability of super-response
based on variables that are currently assessed in clinical practice.
FIGURE 3 | Calibration plot of the AWARD-Class score for super-response to
sacubitril/valsartan.
Predictors of Super-Response to
Sacubitril/Valsartan
Only a few studies have indicated possible predictors for a
favorable response to SV in ambulatory patients with HF
(Martens et al., 2018; Nakou et al., 2018; Vicent et al., 2019;
Chang et al., 2020; Díez-Villanueva et al., 2020) (Table 4). These
are observational cohort studies, most reflecting single-center
experiences, and with a follow-up of less than 1 year after the
start of the drug. The favorable response to SV was defined
as the evidence of a positive cardiac remodeling assessed by
echocardiography or a significant improvement in the functional
capacity of patients. Two studies agreed that higher doses of
SV were more likely to observe a favorable response (Martens
et al., 2018; Chang et al., 2020). Other predictors proposed were
female sex (Vicent et al., 2019), the absence of an ICD (Díez-
Villanueva et al., 2020), the non-ischemic etiology of HF (Chang
et al., 2020), the smaller diameter of the LV (Chang et al., 2020),
and the plasmatic levels of troponin (Nakou et al., 2018). In
this regard, our study coincides in that women were significantly
more frequent “super-responders” than men. This fact has been
equally observed in both the PARAGON-HF trial (McMurray
et al., 2020) and in a pooled analysis with the results of the
PARADIGM trial (Solomon et al., 2020), where SV seemed to
reduce the risk of HF hospitalization more in women than in men
TABLE 4 | Predictors for a favorable response to SV in previous studies.
References N Design FU Response Predictors
Martens et al., 2018 141 Single-center ∼3 m Cardiac remodeling by echo High dose of SV
Nakou et al., 2018 48 Single-center 6 m Functional capacity by CPET Troponin-I
Díez-Villanueva et al., 2020 249 Multi-center ∼7 m Cardiac remodeling by echo Non-ICD
Vicent et al., 2019 427 Multi-center ∼7 m Functional capacity by NYHA Females
Chang et al., 2020 437 Single-center 12 m Cardiac remodeling by echo Non-ischemic, ↓LVEDD, high dose of SV
List of abbreviations: SV, sacubitril/valsartan; FU, follow-up; m, months; CPET, cardio-pulmonary exercise testing; ICD, implantable cardioverter defibrillator; LVEDD, left
ventricular end diastolic diameter.
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in higher values of LVEF, and also with other therapeutic options
for patients with low LVEF such as CRT (Costanzo, 2017).
Smaller LV end diastolic diameter and the absence of previous
ICD were also more prevalent in our super-responder population;
however, these factors were not part of the best equation to
predict the super-response to SV. Instead, the AWARD-Class
score proposes that aldosterone antagonist-naive patients and
those with a previous HF-admission during last year—probably
reflecting subjects with a shorter history of HF—along with better
NYHA class and the absence of diuretics—translating a less
advanced HF stage—are the best predictors for a super-response
to SV in our study population. Supporting the concept of early
initiation of SV, recent randomized clinical trials have shown
that SV initiation during or early after an HF hospitalization—
even in de novo HF—conferred a better prognosis compared to
previous standard treatment (Velazquez et al., 2019; Wachter
et al., 2019b; Senni et al., 2020). Moreover, our model has been
developed integrating populations from two different hospitals
and establishing as a mandatory criterion for super-response
the absence of hard clinical events such as HF readmission,
heart transplantation, or death over the next year, in addition
to positive cardiac remodeling and/or a significant reduction of
NT-proBNP levels. Importantly, this simple score is based on
variables routinely collected in the daily clinical practice and
allows stratifying into three groups according to the probability
of super-response. Indeed, if a patient scores more than 30 points,
the probability of not suffering any clinical event and recovering
at least 10 points of LVEF and/or halve at least their previous
levels of natriuretic peptides after 1 year would be sky high, given
that this group shows a specificity and a positive predictive value
of 100% after internal validation (Table 3).
Clinical Implications
In the outpatient environment, this score should provide the
opportunity to identify those patients who would most benefit
from SV. We consider that its use could imply several clinical
benefits, especially in three scenarios. First, it would help its
implementation in daily clinical practice, which until now has
been slower than expected in different countries (DeVore et al.,
2018; Wachter et al., 2019a; de Frutos et al., 2020). Selecting
patients with a super-response could be particularly helpful in
health systems where resources are limited (Krittayaphong and
Permsuwan, 2018; Kahn et al., 2020). Second, the identification
of a subgroup of patients with an excellent 1-year prognosis
(without events and positive cardiac remodeling) would allow in
turn to differ the potential indication of expensive and invasive
complex therapies, such as CRT or ICD (Zacà, 2018), especially
in patients with non-ischemic cardiomyopathy (Jilek et al., 2020).
And third, the AWARD-Class score fuels the debate on the
timing that SV should be started within the treatment algorithm
of patients with HF and reduced LVEF (Ambrosy et al., 2019;
Escobar et al., 2019).
Study Limitations
Several limitations of this study have to be stated. This was a
retrospective observational study with a relatively small number
of patients. Although the AWARD-Class score includes a wide
range of relevant variables of HF, we did not collect specific
information about other comorbidities or psychosocial factors.
Both hospitals comprised patients from the same geographic
area and mostly Caucasians; thus our model would need further
validation in different populations. In addition, we recognize that
the “super-responder” concept has been defined arbitrarily, but
we have chosen the conditions based on the results of the two
largest studies evaluating NT-proBNP change (Zile et al., 2016)
and cardiac remodeling (Januzzi et al., 2019). Finally, further
studies are warranted to test the performance of this score at
longer follow-ups and in different clinical scenarios such as
acute HF hospitalization or with the addition of new drugs to
the HFrEF armamentarium (McMurray et al., 2019; Ryan and
Maron, 2020; Santos-Gallego et al., 2020; Teerlink et al., 2020).
CONCLUSION
The prevalence of super-responders to SV was of 35% in our
study population. A simple score based on precise variables
that are currently assessed in clinical practice to predict super-
response to SV after 1-year initiation is proposed and should be
validated in different populations.
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